Exchange: OTC·Updated 05:10 PM EDT
About MEDXF
Medexus Pharmaceuticals, Inc. engages in the licensing, acquisition, development, and commercialization of specialty pharmaceutical products in the United States and Canada. The company focuses on therapeutic areas including hematology, hematology-oncology, rheumatology, and allergy. Its principal commercial products include GRAFAPEX, IXINITY, Rasuvo, Metoject, Rupall, and Trecondyv. The company was founded in 2003 and is headquartered in Toronto, Canada.